JHVEPhoto
In briefing documents released ahead of an Advisory Committee meeting this week, FDA staffers cited safety risks related to a combination regimen involving GSK’s (NYSE:GSK) blood cancer drug Blenrep on Tuesday.
Based on data from its late-stage trials, DREAMM-7 and DREAMM-8, the